Massive Bio is a precision oncology company that uses artificial intelligence to match cancer patients with clinical trials and treatment options. Founded in 2015, the company operates across 17 markets and says it has facilitated more than 19,000 clinical trial matches.
Its AI platform analyzes patient profiles to identify trial eligibility, aiming to reduce the manual work involved in connecting patients to appropriate studies. Massive Bio has received the Digital Medicine Society's DiMe Seal and is listed in the Centers for Medicare & Medicaid Services Medicare app library.
The company has formed partnerships across the oncology ecosystem, including collaborations with Foundation Medicine, Prognos Health and, in 2026, the embedded research organization FOMAT to expand AI-powered patient prescreening. Massive Bio is headquartered in Boca Raton, Florida.